Approval · Notice of Compliance 22616 · 2019
KYPROLIS: Notice of Compliance 22616
Issued September 6, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22616
- Date
- September 6, 2019
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a once-weekly dosing regimen in combination with dexamethasone
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KYPROLIS | Not yet assigned | — |
Medicinal ingredients
- CARFILZOMIB 60 MG per VIAL
- CARFILZOMIB 30 MG per VIAL
- CARFILZOMIB 10 MG per VIAL